Transdermal Patch For The Treatment Of Adults With Schizophrenia Available In The U.S.

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., announced that SECUADO transdermal system, a transdermal patch formulation approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with schizophrenia, is now available by prescription in the U.S. It is not known if SECUADO is safe and effective in children who are less than 18 years of age with schizophrenia.

SECUADO was approved by the FDA on October 15, 2019. The patch is applied every 24 hours and is available in three dosage strengths of asenapine: 3.8 mg/24 hour . . .